{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T12:11:28Z","timestamp":1775045488040,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005923","name":"International Association for the Study of Lung Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.cllc.2025.12.006","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T07:48:46Z","timestamp":1766389726000},"page":"59-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Osimertinib-Induced Lung Injury and Treatment Rechallenge: Clinical Insights From a Case Report With a Comprehensive Literature Review"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3096-4452","authenticated-orcid":false,"given":"Fabrizio","family":"Citarella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele C.","family":"Mingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Fiorenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Russano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"La Cava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Santo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Vendittelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Saracino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovica","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Malgeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Ramella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Vincenzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Tonini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Cortellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cllc.2025.12.006_bib0001","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2025.12.006_bib0002","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2019.11.006","article-title":"Patient-reported outcomes from FLAURA: osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer","volume":"125","author":"Leighl","year":"2020","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.cllc.2025.12.006_bib0003","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.cllc.2025.12.006_bib0004","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR -mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.cllc.2025.12.006_bib0005","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR -mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.cllc.2025.12.006_bib0006","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus Lazertinib in previously untreated EGFR -mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.cllc.2025.12.006_bib0007","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41571-024-00938-3","article-title":"The MARIPOSA trials - implications for the treatment of EGFR-mutant NSCLC","volume":"21","author":"Ardeshir-Larijani","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/j.cllc.2025.12.006_bib0008","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.48364","article-title":"Cardiac events and survival in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib","volume":"7","author":"Lin","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.cllc.2025.12.006_bib0009","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/onco.13951","article-title":"First-line osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: outcome and safety in the real world: FLOWER study","volume":"27","author":"Lorenzi","year":"2022","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.cllc.2025.12.006_bib0010","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2217\/cer-2020-0173","article-title":"Factors affecting treatment selection and overall survival for first-line EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer","volume":"10","author":"Kim","year":"2021","journal-title":"J Comp Eff Res"},{"issue":"1","key":"10.1016\/j.cllc.2025.12.006_bib0011","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR -mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.cllc.2025.12.006_bib0012","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR -mutated non\u2013Small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cllc.2025.12.006_bib0013","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","article-title":"TATTON: a multi-arm, phase ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer","volume":"31","author":"Oxnard","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2025.12.006_bib0014","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/annonc\/mdz077","article-title":"Severe immune-related adverse events are common with sequential PD- (L)1 blockade and osimertinib","volume":"30","author":"Schoenfeld","year":"2019","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2025.12.006_bib0015","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s11864-024-01257-6","article-title":"Management of pulmonary toxicities associated with systemic therapy in non small cell lung cancer","volume":"25","author":"Velimirovic","year":"2024","journal-title":"Curr Treat Options in Oncol"},{"issue":"6","key":"10.1016\/j.cllc.2025.12.006_bib0016","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/CAD.0000000000001443","article-title":"Successful osimertinib rechallenge after severe thrombocytopenia caused by osimertinib combined with sitagliptin: a case report","volume":"34","author":"Tan","year":"2023","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.cllc.2025.12.006_bib0017","first-page":"25","article-title":"Successful retreatment with osimertinib after osimertinib-induced acute pulmonary embolism in a patient with lung adenocarcinoma: a case report","volume":"20","author":"Shiroyama","year":"2017","journal-title":"Respir Med Case Rep"},{"issue":"1","key":"10.1016\/j.cllc.2025.12.006_bib0018","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10637-016-0389-9","article-title":"Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody","volume":"35","author":"Mamesaya","year":"2017","journal-title":"Invest New Drugs"},{"issue":"5","key":"10.1016\/j.cllc.2025.12.006_bib0019","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.jtho.2017.01.027","article-title":"Successful osimertinib rechallenge in a patient with T790M-mutant non-small cell lung cancer after osimertinib-induced interstitial lung disease","volume":"12","author":"Miyauchi","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2025.12.006_bib0020","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/j.cllc.2017.06.017","article-title":"Retreatment with osimertinib following pneumonitis","volume":"19","author":"Nagasaka","year":"2018","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2025.12.006_bib0021","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2169\/internalmedicine.8947-17","article-title":"Successful osimertinib rechallenge with steroid therapy after osimertinib-induced interstitial lung disease","volume":"57","author":"Kiriu","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.cllc.2025.12.006_bib0022","first-page":"68","article-title":"Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma","volume":"23","author":"Satoh","year":"2018","journal-title":"Respir Med Case Rep"},{"issue":"7","key":"10.1016\/j.cllc.2025.12.006_bib0023","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2169\/internalmedicine.9609-17","article-title":"EGFR-mutant non-small cell lung cancer accompanied by transient asymptomatic pulmonary opacities successfully treated with \u201cstop-and-go\u201d osimertinib","volume":"57","author":"Kobayashi","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.cllc.2025.12.006_bib0024","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3332\/ecancer.2019.970","article-title":"Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure","volume":"13","author":"Harada","year":"2019","journal-title":"Ecancermedicalscience"},{"issue":"1","key":"10.1016\/j.cllc.2025.12.006_bib0025","doi-asserted-by":"crossref","first-page":"315","DOI":"10.21873\/invivo.11776","article-title":"Osimertinib in Pulmonary manifestations: two case reports and review of the literature","volume":"34","author":"Lu","year":"2020","journal-title":"In Vivo"},{"issue":"6","key":"10.1016\/j.cllc.2025.12.006_bib0026","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2169\/internalmedicine.3689-19","article-title":"Successful Re-administration of osimertinib in osimertinib-induced interstitial lung disease with an organizing pneumonia pattern: a case report and literature review","volume":"59","author":"Itano","year":"2020","journal-title":"Intern Med"},{"issue":"9","key":"10.1016\/j.cllc.2025.12.006_bib0027","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1111\/1759-7714.13565","article-title":"Successful osimertinib retreatment after extremely early onset severe pneumonitis in first-line treatment of lung adenocarcinoma","volume":"11","author":"Ahn","year":"2020","journal-title":"Thorac Cancer"},{"issue":"2","key":"10.1016\/j.cllc.2025.12.006_bib0028","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1159\/000516274","article-title":"Successful rechallenge with osimertinib after very acute onset of drug-induced pneumonitis","volume":"14","author":"Mohammed","year":"2021","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.cllc.2025.12.006_bib0029","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211018028","article-title":"Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies","volume":"13","author":"Bickert","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"22","key":"10.1016\/j.cllc.2025.12.006_bib0030","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1111\/1759-7714.14682","article-title":"Nodule-type pneumonitis mimicking lung abscess or tumor recurrence on chest computed tomography identified as osimertinib-induced pneumonitis: a case report","volume":"13","author":"Otsuki","year":"2022","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.cllc.2025.12.006_bib0031","article-title":"Successful osimertinib rechallenge without concomitant corticosteroids after osimertinib-induced pneumonitis","volume":"49","author":"Ito","year":"2024","journal-title":"Respir Med Case Rep"},{"issue":"12","key":"10.1016\/j.cllc.2025.12.006_bib0032","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.4103\/0366-6999.183426","article-title":"AZD9291-induced acute interstitial Lung Disease","volume":"129","author":"Nie","year":"2016","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.cllc.2025.12.006_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1410684","article-title":"Case report: EGFR-TKI rechallenge after osimertinib-induced interstitial lung disease: a case report and literature review","volume":"15","author":"Gu","year":"2024","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.cllc.2025.12.006_bib0034","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00408-023-00669-9","article-title":"Efficacy and safety of re-administration of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) after EGFR-TKI-induced interstitial lung disease (CS-Lung-005)","volume":"202","author":"Kanaji","year":"2024","journal-title":"Lung."},{"issue":"3","key":"10.1016\/j.cllc.2025.12.006_bib0035","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11523-024-01048-x","article-title":"Real-world data on subsequent therapy for first-line osimertinib-induced pneumonitis: safety of EGFR-TKI rechallenge (Osi-risk Study TORG-TG2101)","volume":"19","author":"Nishioka","year":"2024","journal-title":"Target Oncol"},{"issue":"6","key":"10.1016\/j.cllc.2025.12.006_bib0036","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1177\/03008916211047888","article-title":"Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib","volume":"108","author":"Taronna","year":"2022","journal-title":"Tumori"},{"issue":"6","key":"10.1016\/j.cllc.2025.12.006_bib0037","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/1759-7714.14782","article-title":"TAPO in first-line osimertinib therapy and continuation of osimertinib","volume":"14","author":"Mimura","year":"2023","journal-title":"Thorac Cancer"},{"issue":"12","key":"10.1016\/j.cllc.2025.12.006_bib0038","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/j.jtho.2016.08.144","article-title":"Transient asymptomatic pulmonary opacities occurring during osimertinib treatment","volume":"11","author":"Noonan","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2025.12.006_bib0039","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejca.2022.10.029","article-title":"Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: a multicentre retrospective cohort study","volume":"179","author":"Imaji","year":"2023","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.cllc.2025.12.006_bib0040","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jtho.2018.04.038","article-title":"Transient asymptomatic pulmonary opacities during osimertinib treatment and its clinical implication","volume":"13","author":"Lee","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2025.12.006_bib0041","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.chest.2022.05.035","article-title":"Drug-related pneumonitis induced by osimertinib as first-line treatment for epidermal growth factor receptor mutation-positive non-small cell lung cancer: a real-world setting","volume":"162","author":"Sato","year":"2022","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.cllc.2025.12.006_bib0042","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10637-020-01005-1","article-title":"Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma","volume":"39","author":"Kodama","year":"2021","journal-title":"Invest New Drugs"},{"issue":"10","key":"10.1016\/j.cllc.2025.12.006_bib0043","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S1470-2045(24)00379-6","article-title":"Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis","volume":"25","author":"Zhao","year":"2024","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2025.12.006_bib0044","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.resinv.2024.01.002","article-title":"EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: a multicenter retrospective observational study","volume":"62","author":"Araki","year":"2024","journal-title":"Respir Investig"},{"key":"10.1016\/j.cllc.2025.12.006_bib0045","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.2147\/OTT.S194870","article-title":"Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer","volume":"12","author":"Xu","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"2","key":"10.1016\/j.cllc.2025.12.006_bib0047","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/ijms22020792","article-title":"Molecular and clinical features of EGFR-TKI-associated lung injury","volume":"22","author":"Ohmori","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.cllc.2025.12.006_bib0048","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3892\/ol.2012.872","article-title":"Molecular mechanisms of lung-specific toxicity induced by epidermal growth factor receptor tyrosine kinase inhibitors","volume":"4","author":"Sakao","year":"2012","journal-title":"Oncol Lett"},{"issue":"10","key":"10.1016\/j.cllc.2025.12.006_bib0049","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab deruxtecan in advanced or metastatic non\u2013small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study","volume":"43","author":"Sands","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425003341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425003341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:13:05Z","timestamp":1775041985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425003341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1525730425003341"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.12.006","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osimertinib-Induced Lung Injury and Treatment Rechallenge: Clinical Insights From a Case Report With a Comprehensive Literature Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}